KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Non Operating Income (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Non Operating Income data on record, last reported at $176.0 million in Q4 2025.

  • For Q4 2025, Non Operating Income rose 661.9% year-over-year to $176.0 million; the TTM value through Dec 2025 reached $1.7 billion, up 100.92%, while the annual FY2025 figure was $1.7 billion, 100.92% up from the prior year.
  • Non Operating Income reached $176.0 million in Q4 2025 per REGN's latest filing, down from $768.1 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $768.1 million in Q3 2025 and bottomed at -$197.4 million in Q1 2022.
  • Average Non Operating Income over 5 years is $192.5 million, with a median of $165.4 million recorded in 2021.
  • Peak YoY movement for Non Operating Income: tumbled 227.44% in 2022, then surged 717.95% in 2025.
  • A 5-year view of Non Operating Income shows it stood at $405.6 million in 2021, then plummeted by 66.49% to $135.9 million in 2022, then surged by 42.02% to $193.0 million in 2023, then plummeted by 88.03% to $23.1 million in 2024, then surged by 661.9% to $176.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non Operating Income were $176.0 million in Q4 2025, $768.1 million in Q3 2025, and $439.2 million in Q2 2025.